Benefit-risk balance of COVID drugs. New prospects
Therapie
.
2022 Sep-Oct;77(5):505-507.
doi: 10.1016/j.therap.2022.09.001.
Epub 2022 Sep 6.
Authors
Jean-Luc Cracowski
1
,
Vincent Richard
2
,
Mathieu Molimard
3
Affiliations
1
Department of Medical Pharmacology, Grenoble Alpes University, 38043 Grenoble, France. Electronic address: JLCracowski@chu-grenoble.fr.
2
Department of Medical Pharmacology, Rouen University, 76083 Rouen, France.
3
Department of Medical Pharmacology, Bordeaux University, 33076 Bordeaux, France.
PMID:
36100496
PMCID:
PMC9444335
DOI:
10.1016/j.therap.2022.09.001
No abstract available
Publication types
Editorial
MeSH terms
COVID-19*
Humans
Risk Assessment
SARS-CoV-2